- Home
- CISO vs NRXS Comparison
CISO vs NRXS Comparison
Compare CISO & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- NRXS
- Stock Information
- Founded
- CISO 2015
- NRXS 2011
- Country
- CISO United States
- NRXS United States
- Employees
- CISO N/A
- NRXS N/A
- Industry
- CISO Computer Software: Prepackaged Software
- NRXS
- Sector
- CISO Technology
- NRXS
- Exchange
- CISO Nasdaq
- NRXS Nasdaq
- Market Cap
- CISO 31.4M
- NRXS 25.8M
- IPO Year
- CISO N/A
- NRXS 2023
- Fundamental
- Price
- CISO $1.16
- NRXS N/A
- Analyst Decision
- CISO
- NRXS Strong Buy
- Analyst Count
- CISO 0
- NRXS 1
- Target Price
- CISO N/A
- NRXS $7.00
- AVG Volume (30 Days)
- CISO 960.9K
- NRXS 54.3K
- Earning Date
- CISO 11-17-2025
- NRXS 11-11-2025
- Dividend Yield
- CISO N/A
- NRXS N/A
- EPS Growth
- CISO N/A
- NRXS N/A
- EPS
- CISO N/A
- NRXS N/A
- Revenue
- CISO $28,792,765.00
- NRXS $3,217,531.00
- Revenue This Year
- CISO N/A
- NRXS $62.14
- Revenue Next Year
- CISO N/A
- NRXS $131.87
- P/E Ratio
- CISO N/A
- NRXS N/A
- Revenue Growth
- CISO N/A
- NRXS 41.93
- 52 Week Low
- CISO $0.30
- NRXS $1.33
- 52 Week High
- CISO $3.84
- NRXS $6.20
- Technical
- Relative Strength Index (RSI)
- CISO 55.59
- NRXS N/A
- Support Level
- CISO $1.06
- NRXS N/A
- Resistance Level
- CISO $1.22
- NRXS N/A
- Average True Range (ATR)
- CISO 0.12
- NRXS 0.00
- MACD
- CISO -0.00
- NRXS 0.00
- Stochastic Oscillator
- CISO 65.38
- NRXS 0.00
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).